JACC: CardioOncology - Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitors Trials
Release Date:
Commentary by Corralea Kappel
JACC: CardioOncology - Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitors Trials